SEMA7A and COVID-19: Patients with COVID-19 had significantly higher SEMA3C (1.6 ng/mL, IQR 0.8–2.4 vs. 0.5 ng/mL, IQR 0.2–1.1, p ≤ 0.0001), SEMA3F (4.6 ng/mL, IQR 4.1–6.0 vs. 1.2 ng/mL, IQR 0.9–1.5, p ≤ 0.0001) and SEMA7A (1.5 ng/mL, IQR 0.7–2.7 vs. 0.9 ng/mL, IQR 0.2–1.3, p ≤ 0.0001) concentrations compared to healthy controls (Figure 1a, Table 3).